TY - JOUR
T1 - Interferon-containing and interferon-free HCV therapy for HIV-infected patients
AU - Sulkowski, Mark S.
N1 - Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2014/2
Y1 - 2014/2
N2 - In the era of effective treatment for human immunodeficiency virus (HIV) infection, coinfection with hepatitis C virus (HCV) is an important cause of morbidity and mortality. Similar to other observations made in other HCV-infected patient populations, treatment of chronic HCV infection that results in sustained virologic response or eradication of the hepatitis infection has been strongly associated with decreased likelihood of end-stage liver disease and/or hepatocellular carcinoma and improved overall survival in HIV-infected patients. However, the effectiveness of HCV treatment has been limited due to frequent contraindications to interferon-α (INFα) and prior to the advent of HCV direct acting antivirals, relatively low rates of sustained virologic response. Since 2011, the efficacy of HCV treatment in coinfected patients has improved substantially with the addition of HCV direct-acting antivirals to INFα-based regimens. Based on these observations, there is mounting optimism that INFα-free, oral HCV treatments will further improve efficacy, and more importantly, increase access to treatment for many coinfected patients.
AB - In the era of effective treatment for human immunodeficiency virus (HIV) infection, coinfection with hepatitis C virus (HCV) is an important cause of morbidity and mortality. Similar to other observations made in other HCV-infected patient populations, treatment of chronic HCV infection that results in sustained virologic response or eradication of the hepatitis infection has been strongly associated with decreased likelihood of end-stage liver disease and/or hepatocellular carcinoma and improved overall survival in HIV-infected patients. However, the effectiveness of HCV treatment has been limited due to frequent contraindications to interferon-α (INFα) and prior to the advent of HCV direct acting antivirals, relatively low rates of sustained virologic response. Since 2011, the efficacy of HCV treatment in coinfected patients has improved substantially with the addition of HCV direct-acting antivirals to INFα-based regimens. Based on these observations, there is mounting optimism that INFα-free, oral HCV treatments will further improve efficacy, and more importantly, increase access to treatment for many coinfected patients.
KW - NS5A inhibitors
KW - direct-acting antivirals
KW - hepatitis C virus interferon
KW - human immunodeficiency virus
KW - polymerase inhibitors
KW - protease inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84899619873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899619873&partnerID=8YFLogxK
U2 - 10.1055/s-0034-1371012
DO - 10.1055/s-0034-1371012
M3 - Article
C2 - 24782260
AN - SCOPUS:84899619873
SN - 0272-8087
VL - 34
SP - 72
EP - 78
JO - Seminars in Liver Disease
JF - Seminars in Liver Disease
IS - 1
ER -